{"id":62612,"date":"2026-02-06T22:06:10","date_gmt":"2026-02-06T21:06:10","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/"},"modified":"2026-02-06T22:06:10","modified_gmt":"2026-02-06T21:06:10","slug":"geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/","title":{"rendered":"Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences\u2019 \u2019746 Patent"},"content":{"rendered":"
\n

\nDecision removes last patent hurdle as Geneoscopy advances ColoSense\u00ae, its RNA-based noninvasive colorectal cancer screening test<\/i><\/p>\n

ST. LOUIS–(BUSINESS WIRE)–Geneoscopy, Inc<\/a>., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a Final Written Decision following inter partes<\/i> review (IPR), finding all 10 challenged claims of Exact Sciences\u2019 U.S. Patent No. 11,970,746 (the \u2019746 patent) unpatentable. This decision follows the PTAB\u2019s July 2025 Final Written Decision invalidating all 20 claims of Exact Sciences\u2019 U.S. Patent No. 11,634,781 (the \u2018781 patent). As a result, all patent claims asserted by Exact Sciences against the company in the parties\u2019 ongoing litigation have now been invalidated by the PTAB.<\/p>\n

<\/a>
<\/a><\/p>\n

\nThe PTAB\u2019s ruling concluded that all claims of the \u2019746 patent challenged by the company before the PTAB are unpatentable in view of prior art describing stool sample collection and processing. The PTAB\u2019s decision to invalidate all challenged claims of the \u2018746 patent, following its final decision invalidating all claims of the \u2018781 patent, further confirms Geneoscopy\u2019s long-held position and clears the path for the continued commercialization of ColoSense.<\/p>\n

\n\u201cThe PTAB\u2019s final decisions on these two patents validate what we have believed all along\u2014that the claims in both the \u2019781 patent and the \u2018746 patent being asserted by Exact Sciences against the company should never have been issued,\u201d said Andrew Barnell, CEO and co-founder of Geneoscopy. \u201cThis outcome underscores that invalid patents cannot be used to limit patient access to life-saving colorectal cancer screening options like ColoSense. These final decisions are also a critical step toward protecting patient choice and advancing high-quality, innovative, noninvasive screening solutions.\u201d<\/p>\n

\nGeneoscopy filed the IPR petition after Exact Sciences initiated a patent infringement suit against the company in the U.S. District Court for the District of Delaware. The PTAB\u2019s ruling on the \u2018746 patent removes all of Exact Sciences\u2019 patent challenges against ColoSense in that case, as all patent claims asserted against the company in the litigation have now been invalidated by the PTAB.<\/p>\n

\nAs part of the litigation, Geneoscopy has filed counterclaims against Exact Sciences alleging breach of contract, misappropriation of trade secrets, false advertising, and unfair competition (Exact Sciences Corporation v. Geneoscopy, Inc.,<\/i> C.A. No. 23-1319-MN (D. Del.)).<\/p>\n

\nAbout ColoSense<\/b><\/p>\n

\nColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioM\u00e9rieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc. A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults aged 45 years or older who are at the typical average risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. Results from Geneoscopy\u2019s pivotal CRC-PREVENT trial were published in The Journal of the American Medical Association <\/i>(JAMA) in October 2023. For more information, visit www.colosense.com<\/a>.<\/p>\n

\nAbout Geneoscopy, Inc.<\/b><\/p>\n

\nGeneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy\u2019s mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company\u2019s FDA-approved ColoSense test<\/a> uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit www.geneoscopy.com<\/a> and follow the company on LinkedIn<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:<\/b>
Amit Bhalla
\n
Chief Financial Officer
\n
314 887 7777
\n
Amit.Bhalla@geneoscopy.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Decision removes last patent hurdle as Geneoscopy advances ColoSense\u00ae, its RNA-based noninvasive colorectal cancer screening test ST. LOUIS–(BUSINESS WIRE)–Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62612","6":"format-standard","7":"category-industry"},"yoast_head":"\nGeneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences\u2019 \u2019746 Patent - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences\u2019 \u2019746 Patent - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Decision removes last patent hurdle as Geneoscopy advances ColoSense\u00ae, its RNA-based noninvasive colorectal cancer screening test ST. LOUIS–(BUSINESS WIRE)–Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T21:06:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260206045746\/en\/2714071\/22\/Geneoscopy_Logo_Color_Horizontal-01.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences\u2019 \u2019746 Patent\",\"datePublished\":\"2026-02-06T21:06:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/\"},\"wordCount\":682,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260206045746\\\/en\\\/2714071\\\/22\\\/Geneoscopy_Logo_Color_Horizontal-01.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/\",\"name\":\"Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences\u2019 \u2019746 Patent - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260206045746\\\/en\\\/2714071\\\/22\\\/Geneoscopy_Logo_Color_Horizontal-01.jpg\",\"datePublished\":\"2026-02-06T21:06:10+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260206045746\\\/en\\\/2714071\\\/22\\\/Geneoscopy_Logo_Color_Horizontal-01.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260206045746\\\/en\\\/2714071\\\/22\\\/Geneoscopy_Logo_Color_Horizontal-01.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences\u2019 \u2019746 Patent\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences\u2019 \u2019746 Patent - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/","og_locale":"en_US","og_type":"article","og_title":"Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences\u2019 \u2019746 Patent - Pharma Trend","og_description":"Decision removes last patent hurdle as Geneoscopy advances ColoSense\u00ae, its RNA-based noninvasive colorectal cancer screening test ST. LOUIS–(BUSINESS WIRE)–Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office has issued a ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/","og_site_name":"Pharma Trend","article_published_time":"2026-02-06T21:06:10+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260206045746\/en\/2714071\/22\/Geneoscopy_Logo_Color_Horizontal-01.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences\u2019 \u2019746 Patent","datePublished":"2026-02-06T21:06:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/"},"wordCount":682,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260206045746\/en\/2714071\/22\/Geneoscopy_Logo_Color_Horizontal-01.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/","url":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/","name":"Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences\u2019 \u2019746 Patent - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260206045746\/en\/2714071\/22\/Geneoscopy_Logo_Color_Horizontal-01.jpg","datePublished":"2026-02-06T21:06:10+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260206045746\/en\/2714071\/22\/Geneoscopy_Logo_Color_Horizontal-01.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260206045746\/en\/2714071\/22\/Geneoscopy_Logo_Color_Horizontal-01.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/geneoscopy-wins-second-patent-trial-and-appeal-board-decision-invalidating-all-challenged-claims-of-exact-sciences-746-patent\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Geneoscopy Wins Second Patent Trial and Appeal Board Decision, Invalidating All Challenged Claims of Exact Sciences\u2019 \u2019746 Patent"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62612"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62612\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62612"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62612"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}